Devices for remote monitoring of Parkinson’s disease

1 Purpose of this document

NICE's assessment of devices for remote monitoring of Parkinson's disease recommends that more evidence is generated while the technologies (Kinesia 360, KinesiaU, PDMonitor, Personal KinetiGraph and STAT‑ON) are being used in the NHS.

This plan outlines the evidence gaps and what real-world data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. For assessing comparative treatment effects, randomised controlled trials are the preferred source of evidence if these are able to address the research gap and can be done well.

The companies are responsible for ensuring that data collection and analysis takes place. An approach to evidence generation is through formation of a consortium, bringing analytical partners and implementation sites together with companies.

Guidance on commissioning and procurement of the technologies will be provided by NHS England, who are developing a digital health technology policy framework to further outline commissioning pathways.

NICE will withdraw the guidance if the companies do not meet the conditions in section 4 on monitoring.

After the end of the evidence generation period (4 years), the companies should submit the evidence to NICE in a form that can be used for decision making. NICE will review all the evidence and assess whether the technologies can be routinely adopted in the NHS.